Oric Pharmaceuticals Total Operating Expenses History

ORIC Stock  USD 11.10  -0.03  -0.27%   
Its Total Operating Expenses has been contracting recently. Total Operating Expenses can be found on Oric Pharmaceuticals''s income statement. The latest Total Operating Expenses reading is 86.7 M, compared with 141.8 M a year ago (down 63.45%). View All Financial Accounts
 
Total Operating Expenses  
 First Reported
2019-03-31
 Previous Quarter
36.7 M
 Current Value
34.2 M
 Quarterly Volatility
10.4 M
Macro event markers
 
Covid
 
Interest Hikes

Latest Oric Pharmaceuticals' Total Operating Expenses Growth Pattern

Oric Pharmaceuticals's Total Operating Expenses across 9 years of filings is presented below. Periods of stability and acceleration are both visible in the long-term series. Contextualizing the current level against the historical series helps gauge whether it is elevated or compressed. Evaluating Oric Pharmaceuticals' Total Operating Expenses against peer averages adds another layer of context. The curvature of Oric Pharmaceuticals' Total Operating Expenses trend adds context beyond what the raw numbers convey.
Total Operating Expenses10 Years Trend
Slightly volatile
All figures are presented for informational review.
   Total Operating Expenses   
       Timeline  

Total Operating Expenses Trend Statistics

Arithmetic Mean 55,762,127
Geometric Mean 41,372,805
Coefficient Of Variation 80.29
Mean Deviation 39,359,209
Median 22,371,000
Standard Deviation 44,769,001
Sample Variance2004.3T
Range120.1M
R-Value 0.85
Mean Square Error581.3T
R-Squared 0.73
Significance 0.000013
Slope 7,564,841
Total Sum of Squares32068.2T

Oric Pharmaceuticals Total Operating Expenses History

202686.7 M
2025141.8 M
2024141.8 M
2023109.7 M
202291.8 M
202178.9 M
202074.2 M
201927.6 M
201822.4 M

Related Accounts

Last ReportedEnd Of Year Estimate
Selling And Marketing Expenses1.2 M1.1 M
Other Operating Expenses143 M87.4 M
Total Operating Expenses141.8 M86.7 M

Methodology, Assumptions & Data Sources

Below is Oric Pharmaceuticals's Total Operating Expenses history. A strong fit to a straight line suggests the trend is dependable.

Inputs for Oric Pharmaceuticals come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Analyst inputs may be included when coverage is available. Some fields can appear with publication lag. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Michael Smolkin - Member of Macroaxis Board of Directors
Last reviewed on March 18th, 2026